Latest News - Regeneron Pharmaceuticals

Monday, December 11, 2017 | Retina, Regeneron Pharmaceuticals

Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of Eylea (aflibercept) for Patients with Wet AMD

Regeneron announced that the FDA has accepted for review the company's supplemental Biologics License Application for a 12-week dosing interval of Eylea (aflibercept) injection in patients with we…

Read the full story

Monday, November 27, 2017 | Clinical Trials, Regeneron Pharmaceuticals

Regeneron Ends Clinical Program of Eylea and Nesvacumab (Ang2 Antibody) Combination

Regeneron announced that results from two phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to Eylea (aflibercept) injection did not provide sufficient differentiation to warrant…

Read the full story

Friday, August 04, 2017 | Earnings & Financials, Regeneron Pharmaceuticals

Regeneron's Second-Quarter Revenue Rises 21 Percent on Higher Eylea Sales

Regeneron Pharmaceuticals announced that revenue for the second quarter jumped 21 percent to $1.5 billion, beating analyst estimates of $1.4 billion, fuelled by 11-percent growth in Eyl…

Read the full story

Friday, February 10, 2017 | Earnings & Financials, Regeneron Pharmaceuticals

Regeneron Forecasts 2017 US Eylea Sales Growth Below Estimates

Regeneron Pharmaceuticals forecast 2017 U.S. sales growth for its flagship eye drug Eylea that fell short of analysts' estimates, pushing its shares down 2.3 percent in premarket trading. The U.S.…

Read the full story

Thursday, October 13, 2016 | Partnerships, Retina, Ocular Therapeutix, Regeneron Pharmaceuticals

Ocular Therapeutix and Regeneron Collaborate to Develop a Sustained-Release Formulation of Aflibercept for Wet AMD and Other Retinal Diseases

In a deal that could be worth more than $300 million, Ocular Therapeutix announced that it has entered into a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals to c…

Read the full story

Friday, September 30, 2016 | Clinical Trials, Retina, Regeneron Pharmaceuticals

Combination Therapy Shows No Benefit Over Aflibercept Alone in Phase 2 AMD Trial

The phase 2 CAPELLA study evaluating aflibercept (Eylea, Regeneron) coformulated with rinucumab (Regeneron), an anti-platelet-derived growth factor (anti-PDGF) receptor beta antibody, in patients with…

Read the full story

Friday, August 05, 2016 | Earnings & Financials, Regeneron Pharmaceuticals

Regeneron Posts 27% Growth in US Sales of Eylea for Q2

Regeneron Pharmaceuticals on Thursday announced that second-quarter sales of Eylea in the US climbed 27 percent year-over-year to $831 million, ahead of analyst forecasts of $812 m…

Read the full story

Thursday, May 26, 2016 | Awards, Regeneron Pharmaceuticals

Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search

Society for Science & the Public announced that Regeneron Pharmaceuticals is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from …

Read the full story

Wednesday, May 25, 2016 | Retina, Regeneron Pharmaceuticals

Regeneron Announces US Prescribing Information Clarification for Eylea Injection

Regeneron Pharmaceuticals announced that the FDA has approved an update to the dosage and administration section of the Eylea (aflibercept) Injection US Prescribing Information for patients with neova…

Read the full story

Sunday, February 28, 2016 | Clinical Trials, Retina, Genentech, Regeneron Pharmaceuticals

Protocol T: 2-Year Data Released

All three anti-VEGF agents evaluated in the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T trial were effective in treating diabetic macular edema (DME) at 2 years, according to …

Read the full story

Wednesday, August 05, 2015 | Earnings & Financials, Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Profit, Sales Beat Views

Regeneron Pharmaceuticals Inc., which recently won approval for its cholesterol drug, said profit doubled in its second quarter as sales of its eye-disease treatment surged.

Read the full story

Friday, May 08, 2015 | Earnings & Financials, Retina, Regeneron Pharmaceuticals

Eylea Sales Exceed Expectations; Regeneron Boosts 2015 Guidance for the Drug

Sales of Eylea (aflibercept) in the United States increased 51% to $541 million in the first quarter of 2015, topping analyst estimates of about $526 million. Regeneron also raised its 2015 full-year …

Read the full story

Thursday, April 16, 2015 | Management/Leadership, Regeneron Pharmaceuticals

Regeneron CEO Joins Cuba Trade Trip With New York Governor Cuomo

Regeneron Pharmaceuticals Inc.'s top executive will join New York Governor Andrew Cuomo on a trade mission to Cuba, home to a state-sponsored biopharmaceutical industry, as the island nation&rsquo…

Read the full story

Wednesday, March 25, 2015 | FDA Approval/Clearance, Regeneron Pharmaceuticals

Eylea Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with DME

Regeneron announced that the FDA has approved Eylea (aflibercept) injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME), according to a company news release…

Read the full story

Friday, February 27, 2015 | Retina, Regeneron Pharmaceuticals

Eylea Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

Regeneron Pharmaceuticals announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular edema secondary to retinal vei…

Read the full story
Load More